[Wall Street Journal] TYSABRI- FDA Will Weigh Return to Market Of Drug for MS: "The Food and Drug Administration will convene a panel of outside medical experts on March 7 to help determine whether Tysabri, a treatment for multiple sclerosis, should be allowed to return to the market.

The FDA typically follows its panels' advice but isn't required to. The FDA is expected to make a final decision on Tysabri's fate by the end of March.
Biogen, Cambridge, Mass., and Elan, based in Ireland, said yesterday a review of about 3,000 patients who had taken Tysabri showed no new cases of PML"